
Novartis has bought the rights to licence and commercialise a novel anti-PGDF therapy which it is currently trialling in Phase …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

